| 000 | 01891 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250516212024.0 | ||
| 264 | 0 | _c20140925 | |
| 008 | 201409s 0 0 eng d | ||
| 022 | _a0946-1965 | ||
| 024 | 7 |
_a10.5414/CP202091 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aDe Kam, Pieter-Jan | |
| 245 | 0 | 0 |
_aLack of a clinically relevant effect of sugammadex on anti-Xa activity or activated partial thromboplastin time following pretreatment with either unfractionated or low-molecular-weight heparin in healthy subjects. _h[electronic resource] |
| 260 |
_bInternational journal of clinical pharmacology and therapeutics _cAug 2014 |
||
| 300 |
_a631-41 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 |
_aAnticoagulants _xpharmacology |
| 650 | 0 | 4 | _aCross-Over Studies |
| 650 | 0 | 4 | _aDose-Response Relationship, Drug |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 | _aDrug Interactions |
| 650 | 0 | 4 |
_aEnoxaparin _xpharmacology |
| 650 | 0 | 4 | _aFactor Xa Inhibitors |
| 650 | 0 | 4 |
_aHeparin _xpharmacology |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aPartial Thromboplastin Time |
| 650 | 0 | 4 | _aSugammadex |
| 650 | 0 | 4 | _aYoung Adult |
| 650 | 0 | 4 |
_agamma-Cyclodextrins _xadministration & dosage |
| 700 | 1 | _aKruithof, Annelieke C | |
| 700 | 1 | _avan Lierop, Marie-José | |
| 700 | 1 | _aMoerland, Matthijs | |
| 700 | 1 | _aDennie, Justin | |
| 700 | 1 | _aTroyer, Matthew D | |
| 700 | 1 | _aLangdon, Ronald B | |
| 700 | 1 | _aGutstein, David E | |
| 700 | 1 | _aBurggraaf, Jacobus | |
| 700 | 1 | _aEl Galta, Rachid | |
| 773 | 0 |
_tInternational journal of clinical pharmacology and therapeutics _gvol. 52 _gno. 8 _gp. 631-41 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.5414/CP202091 _zAvailable from publisher's website |
| 999 |
_c23800288 _d23800288 |
||